Oxford PharmaGenesis was proud to present the results of its research into the benefits of medical writing support for randomized controlled trial (RCT) reporting at the fifth Evidence Live conference, held at the University of Oxford, 22–24 June 2016.

Oxford PharmaGenesis is celebrating a third award for their original research demonstrating that professional medical writing support improves the quality of clinical trial reporting. “We’re delighted that our independent research has again been recognized as an important milestone for our industry”, says co-author and Commercial Director, Dr Richard White.

Oxford PharmaGenesis recently attended the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held in Washington, DC (21–25 May 2016). There was a wide variety of stakeholders in market access and health economics and outcomes research (HEOR) from the pharmaceutical industry, government agencies and academia at the meeting, as…

This month Dr Richard White, our Commercial Director, and Dr Paul Farrow, Communications Director, gave expert talks at the first ever MedComms Brunch Club in Oxford. The links to these talks are below; for further information please click here. Many thanks, as always, to Peter Llewellyn (NetworkPharma) for inviting us to take part in this…

A leading European magazine, Pharmaceutical Marketing Europe, has turned to Oxford PharmaGenesis to update European pharmaceutical executives on how to plan and run advisory board meetings in the digital age.

Medical writers from across Europe gathered in Munich at the 42nd European Medical Writers Association Conference (EMWA, 10–14 May 2016) to network, share best practice and look to the future.